Lab members in bold.

Molina-Sánchez P, Ruiz de Galarreta M, Yao MA, Lindblad KE, Bresnahan E, Bitterman E, Martin TC, Rubenstein T, Nie K, Golas J, Choudhary S, Bárcena-Varela M, Elmas A, Miguela V, Ding Y, Kan Z, Grinspan LT, Huang KL, Parsons RE, Shields DJ*, Rollins RA*, Lujambio A*. Cooperation between distinct cancer driver genes underlies inter-tumor heterogeneity in hepatocellular carcinoma. Gastroenterology. 2020 Aug 16:S0016-5085(20)35054-X. doi: 10.1053/j.gastro.2020.08.015. *Co-corresponding author.

Bresnahan E, Lindblad KE, Ruiz de Galarreta M, Lujambio A. Mouse models of oncoimmunology in hepatocellular carcinoma. Clin Cancer Res, 10.1158/1078-0432.CCR-19-2923 (2020).

Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, Navrazhina K, Cao Z, Choi D, Huang CH, Linton E, Chen X, Liang Y, Mason CE, de Stanchina E, Abida W, Lujambio A, Li S, Lowe SW, Mendell JT, Malladi VS, Sawyers CL, Mu P. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell, Apr 13;37(4):584-598.e11 (2020).

Bresnahan E, Ramadori P, Heikenwalder M, Zender L, Lujambio A. Novel patient-derived models of liver cancer. J Hepatol, 72 (2), 239-249 (2020).

Lozano T, Chocarro S, Martin C, Lasarte-Cia A, Del Valle C, Gorraiz M, Sarrion P, Ruiz de Galarreta M, Lujambio A, Hervaz-Stubbs S, Sarobe P, Casares N, Lasarte JJ. Genetic modifications of CD8+ T cells to express EGFR: potential application for adoptive T cell therapies. Front Immunol, 20;10:2990 (2019).

Ruiz de Galarreta M, Bresnahan E, Maier B, Molina-Sánchez P, Sia S, Casanova-Acebes M, Dhainaut M, Miguela V, Puigvehi M, Villacorta-Martin C, Monga S.P, Villanueva A, Brown B.D, Llovet J.M, Merad M, Lujambio A. β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discovery (2019).

Wang S, Zhang C, Hasson D, Desai A, SenBanerjee S, Ukomadu C, Lujambio A, Bernstein E, Sadler K.C. Epigenetic compensation promotes liver regeneration. Developmental Cell (2019).

Yu J.X, Craig A.J, Villacorta-Martin C, Miguela V, Ruiz de Galarreta M, Scopton A.P, Silber L, Maldonado A.Y, Duffy M.E, Lujambio A*, Villanueva A*, Dar A.C.* Phenotype-based screens with conformation-specific inhibitors reveal p38 gamma and delta as therapeutic targets in HCC. Accepted in Molecular Cancer Therapeutics (2019). *Co-corresponding author.

Ruiz de Galarreta M, Lujambio A. Hepatocellular carcinoma: killing one bird with two stones. Gut. Online (2019).

Lujambio A, Banito A. Functional screening to identify senescence regulators in cancer. 54:17-24. Current Opinion in Genetics and Development (2019).

Molina-Sanchez P, Lujambio A. Iron overload and liver cancer. 216(4):723-724. Journal of Experimental Medicine (2019).

Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, P. Koh A, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J. Nuclear pores promote lethal prostate cancer by increasing E2F1, MYC and AR-related signaling activity. 174(5):1200-1215. Cell (2018).

Ruiz de Galarreta M, Lujambio A. DNA sensing in senescence. Nat Cell Biol 2017 Aug 31;19(9):1008-1009. doi: 10.1038/ncb3603.

Deshmukh M, Nakagawa S, Higashi T, Vincek A, Venkatesh A, Ruiz de Galarreta M, Koh AP, Goossens N, Hirschfield H, Bian CB, Fujiwara N, Ono A, Hoshida H, El-Abtah M, Ahmad NB, Lujambio A, Sanchez R, Fuchs BC, Poelstra K, Prakash J, Hoshida Y; Precision Liver Cancer Prevention Consortium. Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine 2017 Nov 20;14(2):317-325. doi: 10.1016/j.nano.2017.11.004.

Ruiz de Galarreta M, Lujambio A. Therapeutic editing of hepatocyte genome in vivo. J Hepatol 2017 Oct;67(4):818-828. doi: 10.1016/j.jhep.2017.05.012.

Molina-Sánchez P, Lujambio A. Strategies for HCC target discovery. Aging (Albany NY) 2017 Apr;9(4):1088-1089. doi: 10.18632/aging.101233.

Rapisarda V, Borghesan M, Miguela V, Encheva V, Snijders AP, Lujambio A, O’Loghlen A. Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway. Cell Rep 2017 Mar 7;18(10):2480-2493. doi: 10.1016/j.celrep.2017.02.012.

Valerio DG, Xu H, Chen CW, Hoshii T, Eisold ME, Delaney C, Cusan M, Deshpande AJ, Huang CH, Lujambio A, Zheng YG, Zuber J, Pandita TK, Lowe SW, Armstrong SA. Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res 2017 Feb 15. doi: 10.1158/0008-5472.CAN-16-2374. [Epub ahead of print]

Fraile JM, Manchado E, Lujambio A, Quesada V, Campos-Iglesias D, Webb TR, Lowe SW, López-Otín C, Freije JM. USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. J Biol Chem 2017 Mar 10;292(10):4164-4175. doi: 10.1074/jbc.M116.762757. Epub 2017 Feb 1.

Miguela V, Lujambio A. Uncovering the role of USP54 in cancer. Oncotarget. 2017 Jan 26. doi: 10.18632/oncotarget.14820. [Epub ahead of print]

Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sanchez P, Nguyen C, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumor growth in preclinical models of hepatocellular carcinoma. In press in Gut (2016).

Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM. IGF2 is up-regulated by epigenetic mechanisms in hepatocellular carcinoma and is an actionable oncogene in experimental models. S0016-5085. Gastroenterology (2016).

Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu BX, Zhang C, Bollag G, de Stanchina E, Herlyn M, Lujambio A, Gavathiotis E, Poulikakos PI. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell S1535-6108(16)30284-7 (2016).

Manchado E, Weissmueller S, Morris JP IV, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran FB, Engelman A, Rudin CM, Rosen N, Lowe SW. A combinatorial strategy for treating KRAS mutant lung cancer. Nature. 30;534(7609):647-51 (2016).

Lujambio A. To clear or not to clear (senescent cells)? That is the question. Bioessays S56-64 (2016).

Lujambio A, Villanueva A. The usual SASPects of liver cancer. Aging. 7(6):348-349 (2015)

Vidal SJ, Rodriguez-Bravo V, Quinn SA, Lujambio A, Rodriguez-Barrueco R, Hoshida Y, Petrylak DP, Rabadan R, Silva J, Lowe SW, Cordon-Cardo C, Domingo-Domenech J. Therapeutic targeting of a GATA2-IGF2 axis in lethal prostate cancer. Cancer Cell 27(2):223-39 (2015).

Huang CH*, Lujambio A*, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes & Development 28:1800-1814 (2014). * equal contribution.

Elizalde M, Urtasun R, Azkona M, Latasa MU, Goñi S, García-Irigoyen O, Uriarte I, Segura V, Collantes M, Di Scala M, Lujambio A, Prieto J, Ávila MA, Berasain C. Slu7 is an essential factor for the preservation of liver differentiation, metabolic function and quiescence. Journal of Clinical Investigation 124(7):2909-20 (2014).

Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA, Krizhanovsky V, Lowe SW. Non-cell-autonomous tumor suppression by p53.  Cell 153(2):449-60 (2013).

Carmona FJ, Villanueva A, Vidal A, Muñoz C, Puertas S, Penin RM, Gomà M, Lujambio A, Piulats JM, Mesía R, Sánchez-Céspedes M, Manós M, Condom E, Eccles SA, Esteller M. Epigenetic Disruption of Cadherin-11 in Human Cancer Metastasis. J Pathol doi: 10.1002/path.4011 (2012).

Lujambio A, Lowe SW. The microcosmos of cancer. Nature 15;482(7385):347-55 (2012).

Iliou MS, Lujambio A, Portela A, Brüstle O, Koch P, Andersson-Vincent PH, Sundström E, Hovatta O, Esteller M. Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer. Epigenetics 1;6(11) (2011).

Vegliante MC, Royo C, Palomero J, Salaverria I, Balint B, Martín-Guerrero I, Agirre X, Lujambio A, Richter J, Xargay-Torrent S, Bea S, Hernandez L, Enjuanes A, Calasanz MJ, Rosenwald A, Ott G, Roman-Gomez J, Prosper F, Esteller M, Jares P, Siebert R, Campo E, Martín-Subero JI, Amador V. Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications. PLoS One 6(6):e21382 (2011).

Lujambio A, Portela A, Liz J, Melo SA, Rossi S, Spizzo R, Croce CM, Calin GA, Esteller M. CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene 29(48):6390-6401 (2010).

Fernandez AF, Rosales C, Lopez-Nieva P, Grana O, Ballestar E, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF, Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban JI, Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, Gaidano G, Cigudosa JC, Gomez-Lopez G, Pisano DG, Valencia A, Piris MA, Bosch FX, Cahir-McFarland E, Kieff E, Esteller M. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 19(3):438-451 (2009).

Lujambio A, Esteller M. How epigenetics can explain human metastasis: A new role for microRNAs. Cell Cycle 8(3): 377-382 (2009).

Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 105(36): 13556-13561 (2008).

Blanco D, Vicent S, Fraga MF, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, Lecanda F, Montuenga LM. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia 9(10): 840-852 (2007).

Lujambio A, Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 6(12): 1455-1459 (2007).

Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Git A, Spiteri I, Das PP, Caldas C, Miska E, Esteller M. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67(4): 1424-1429 (2007).